Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20514063 | 0.86 | POLB (0.64) | HPGDALDH1A1KDM4EGAARAB9A | |
| SCHEMBL23026169 | 0.85 | HPGD (0.60) | HPGDALDH1A1KDM4EGAARAB9A | |
| SCHEMBL20514117 | 0.84 | HTT (0.43) | HPGDALDH1A1KDM4EGAARAB9A | |
| SCHEMBL20514264 | 0.83 | GAA (0.47) | HPGDALDH1A1KDM4EGAARAB9A | |
| SCHEMBL20514128 | 0.82 | ALDH1A1 (0.49) | HPGDALDH1A1GAARAB9ANPC1 | |
| SCHEMBL20514150 | 0.81 | ALDH1A1 (0.48) | HPGDALDH1A1GAARAB9ANPC1 | |
| SCHEMBL20514136 | 0.81 | HPGD (0.56) | HPGDALDH1A1KDM4EGAARAB9A | |
| SCHEMBL23026172 | 0.80 | HPGD (0.44) | HPGDALDH1A1KDM4ERAB9ANPC1 | |
| SCHEMBL20514204 | 0.78 | GAA (0.64) | HPGDALDH1A1KDM4EGAARAB9A | |
| SCHEMBL20190340 | 0.77 | APLNR (0.49) | HPGDALDH1A1KDM4EGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3380970-B1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3380970-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | HPGD 4292/4885ALDH1A1 2642/4885KDM4E 1867/4885 |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | HPGD 4292/4885ALDH1A1 2642/4885KDM4E 1867/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | HPGD 4302/4885ALDH1A1 2968/4885KDM4E 1779/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | HPGD 4319/4885ALDH1A1 2845/4885KDM4E 1815/4885 |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | HPGD 4280/4885ALDH1A1 2828/4885KDM4E 1792/4885 |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | HPGD 4244/4885ALDH1A1 2622/4885KDM4E 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.